What Is the Difference Between Dementia and Alzheimer’s?

Dementia is not a single disease but an umbrella term for a decline in memory, reasoning, or daily functioning severe enough to interfere with independent life. Alzheimer’s disease is the most common cause, accounting for an estimated 60 to 80 percent of dementia cases. The confusion between the two terms is widespread, and the distinction matters: understanding that Alzheimer’s is one specific brain disease under the broader dementia umbrella shapes how the condition is diagnosed, treated, and researched.

Why the Distinction Between Dementia and Alzheimer’s Matters

Saying someone “has dementia” is a bit like saying they “have an infection.” It tells you something is wrong but not what is causing it. Dementia describes a set of symptoms, chiefly progressive cognitive decline, that can stem from dozens of underlying diseases. Alzheimer’s is one of those diseases, and it happens to be the most prevalent. Others include vascular dementia, dementia with Lewy bodies, and frontotemporal dementia, each with its own brain pathology, symptom profile, and trajectory.

The distinction is not just academic. Treatments that target Alzheimer’s biology, such as the newer anti-amyloid antibodies, would not be expected to help someone whose cognitive decline comes from repeated small strokes. Getting the right diagnosis also affects prognosis, care planning, and genetic counseling. A family history of early-onset Alzheimer’s carries different implications than a family history of vascular dementia linked to uncontrolled high blood pressure.

What Happens in the Brain During Alzheimer’s

Two abnormal protein buildups define Alzheimer’s at the tissue level. The first involves amyloid-beta, a small protein fragment that clumps into plaques outside brain cells, particularly in the frontal cortex and hippocampus. Whether the brain accumulates too much amyloid-beta depends on how fast it is produced and how efficiently the brain clears it away; growing evidence points to impaired clearance as a key driver of the buildup rather than simple overproduction.¹²

The second hallmark is neurofibrillary tangles made of a protein called tau. In a healthy brain, tau stabilizes the internal scaffolding of nerve cells. In Alzheimer’s, tau becomes abnormally loaded with phosphate groups, detaches from that scaffolding, and clumps into tangled filaments inside neurons.³ Research using brain imaging in living people has shown that tau spreads through the brain’s communication pathways, and that amyloid-beta accelerates this spread. Regions with more amyloid plaque tend to accumulate more tau than their connectivity alone would predict.⁴

Inflammation adds a third layer of damage. The brain’s resident immune cells, microglia, cluster around amyloid plaques. On one hand, they try to engulf and remove amyloid. On the other, their activation releases toxic molecules that damage surrounding neurons. This dual role makes microglia both part of the defense and part of the problem.⁵

Other Common Causes of Dementia

Because dementia has multiple causes, knowing which one is at work changes almost everything about care and outlook.

Vascular dementia results from damage to the brain’s blood supply. The underlying pathology is distinct from Alzheimer’s: rather than amyloid plaques and tau tangles, the brain shows infarcts, areas where tissue has died due to blocked or burst blood vessels.⁶ In pure vascular dementia, roughly two-thirds of these lesions are small, deep infarcts in subcortical areas. When Alzheimer’s and vascular disease coexist, a condition called mixed dementia, the pattern shifts toward larger, more widespread damage.⁷ Mixed dementia is common and often goes unrecognized because one pathology overshadows the other during a clinical workup.

Dementia with Lewy bodies involves clumps of a different protein, alpha-synuclein, inside nerve cells. Compared with Alzheimer’s, Lewy body dementia tends to hit attention and executive function harder early on, while memory may be relatively spared at first. People with Alzheimer’s, by contrast, typically show worse memory deficits on formal testing but better attention. When Lewy bodies and Alzheimer’s pathology occur together, cognitive decline tends to be steepest of all.⁸ Autopsy studies confirm that pure Lewy body disease and Alzheimer’s are distinct at the tissue level, though both can feature diffuse amyloid plaques.⁹

Frontotemporal dementia stands apart from Alzheimer’s in both age of onset and symptoms. It typically strikes earlier, often before age 65, and its initial symptoms are more likely to be changes in personality, social behavior, or language rather than memory loss. The underlying pathology involves proteins like tau, TDP-43, or FUS, and more than 20 causative genes have been identified.¹⁰

A Recently Recognized Condition in the Oldest Old

One of the more important developments in dementia science over the past decade is the recognition of limbic-predominant age-related TDP-43 encephalopathy, or LATE. This condition mimics Alzheimer’s clinically but involves a different misfolded protein, TDP-43, concentrated in the brain’s limbic regions. In population-based studies of people who died at very advanced ages, LATE was independently associated with dementia and was among the strongest predictors of cognitive decline, with a higher attributable risk for dementia than Alzheimer’s pathology itself in some models.¹¹ LATE frequently coexists with both Alzheimer’s pathology and Lewy bodies, and each pathology independently worsens cognition beyond what Alzheimer’s alone would produce.¹²

LATE matters for patients and families because it helps explain why some people diagnosed with Alzheimer’s do not respond as expected to Alzheimer’s-specific treatments. If the underlying driver is TDP-43 rather than amyloid, clearing amyloid plaques may offer little benefit. Until recently, LATE could only be confirmed at autopsy. Its growing recognition is pushing researchers to develop ways to identify it in living patients.

Genetics and Family History

A small fraction of Alzheimer’s cases, typically striking before age 65, are caused by inherited mutations in three genes: APP, PSEN1, and PSEN2. These mutations are autosomal dominant, meaning a single copy passed from one parent is enough to cause the disease, often in a person’s 40s or 50s.¹³¹⁴

The far more common late-onset form of Alzheimer’s is not caused by a single gene but influenced by many. The strongest genetic risk factor is a variant of the APOE gene called APOE-ε4. Carrying one copy roughly triples the risk compared to the most common variant; carrying two copies increases it more. But APOE-ε4 is a risk factor, not a destiny. Many carriers never develop Alzheimer’s, and many people who get the disease do not carry the variant. Interestingly, APOE-ε4 appears to affect brain function throughout life, not only in old age: young carriers have been found to outperform non-carriers on certain cognitive tasks, while imaging shows distinct patterns of brain activity in their temporal lobes.¹⁵

Blood Tests Are Changing Early Detection

For decades, confirming Alzheimer’s pathology in a living person required either a lumbar puncture for spinal fluid analysis or a PET brain scan, both expensive and not widely available. That landscape is shifting rapidly thanks to blood-based biomarkers, particularly tests measuring a form of tau called p-tau217.

A plasma test combining p-tau217 with amyloid-beta 42 achieved an accuracy above 96 percent for detecting abnormal amyloid on PET scans, performing on par with spinal fluid tests.¹⁶ Another large study of p-tau217 alone found it could correctly classify about 92 percent of participants as amyloid-positive or amyloid-negative when using a two-threshold approach, with only about 18 percent falling into an indeterminate zone requiring further testing.¹⁷ Across multiple independent cohorts, the ALZpath p-tau217 immunoassay showed similarly high accuracy for identifying both amyloid and tau pathology, comparable to spinal fluid markers.¹⁸

These blood tests are not yet standard care everywhere, but their rollout is accelerating. For patients, the practical impact is significant: a routine blood draw at a primary care office could eventually replace the need for a specialist visit, a PET scan, or a spinal tap as the first step in diagnosis. The tests also matter for clinical trials, where enrolling only participants with confirmed brain amyloid is essential but currently slow and expensive.

Risk Factors You Can Influence

Age and genetics sit beyond anyone’s control, but a substantial share of dementia risk is tied to factors that can be managed. Vascular risk factors such as high blood pressure and diabetes not only drive vascular dementia directly but also appear to increase the risk of Alzheimer’s itself, likely by accelerating the accumulation of neurotoxic proteins in the brain.¹⁹

Hearing loss has emerged as one of the most consistently identified modifiable risk factors. A meta-analysis found that age-related hearing loss was significantly associated with faster cognitive decline and a higher risk of dementia.²⁰ A population-based prospective study put the hazard ratio at about 1.28, meaning people with hearing loss had roughly a 28 percent higher chance of developing dementia after controlling for age, sex, education, and cardiovascular risk.²¹ The mechanism is not fully settled, but possibilities include the cognitive load of straining to hear, social isolation that follows hearing difficulty, and shared vascular damage to both the inner ear and the brain.

Sleep is another area drawing intense research attention. During deep slow-wave sleep, the brain’s waste-clearance system, sometimes called the glymphatic system, becomes most active. The spaces between brain cells expand, and cerebrospinal fluid flows more freely to flush out metabolic waste, including amyloid-beta.²² Chronic sleep disruption could, in theory, allow amyloid to accumulate faster than the brain can remove it. This does not mean poor sleep causes Alzheimer’s in any simple sense, but it adds to the rationale for treating sleep disorders aggressively, particularly in middle and later life.

Education, Activity, and Cognitive Reserve

The concept of cognitive reserve helps explain a puzzling observation: some people harbor significant Alzheimer’s pathology in their brains yet function normally, while others with less pathology are already impaired. Epidemiological data suggests that education, occupational complexity, and mentally stimulating leisure activities build a buffer that allows the brain to tolerate more damage before symptoms emerge.²³

A systematic review and meta-analysis found that higher cognitive reserve was protective against dementia whether it was built in early life, midlife, or late life, with hazard ratios ranging from about 0.81 to 0.91 across these periods.²⁴ A separate large meta-analysis focused specifically on education found robust evidence that higher education reduces both the prevalence and the incidence of Alzheimer’s, vascular dementia, and nonspecific dementia. The same analysis noted a counterintuitive wrinkle: once clinical symptoms do appear, more educated individuals tend to decline faster, likely because they had been compensating for more underlying damage before hitting a threshold.²⁵

Physical exercise also appears to support brain health, in part by boosting levels of brain-derived neurotrophic factor (BDNF), a protein that promotes the survival and growth of neurons. The effect has been documented most clearly in younger adults, with the relationship in older adults and people with existing neurodegeneration still being mapped out.²⁶

Current Treatments

Medications for Alzheimer’s fall into two broad categories: those that manage symptoms and those that target the underlying disease biology.

The older, established drugs are cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine. They work by slowing the breakdown of acetylcholine, a brain chemical involved in memory and learning that is depleted in Alzheimer’s.²⁷ A network meta-analysis of 41 randomized controlled trials found that for mild to moderate Alzheimer’s, galantamine and donepezil were the most effective options for cognition, while for moderate to severe disease, combining memantine with donepezil was recommended. Memantine works differently, blocking overactivation of a receptor involved in learning signals that, when chronically overstimulated, damages neurons. Rivastigmine delivered through a skin patch showed the best results for daily functioning. None of these drugs significantly improved behavioral symptoms like agitation or apathy.²⁸

The newer class of treatments consists of anti-amyloid monoclonal antibodies, including lecanemab and donanemab. These drugs are designed to bind to amyloid-beta and help the body clear it from the brain. Large placebo-controlled trials have shown they can slow the rate of cognitive and functional decline.²⁹ The slowing is real but modest, and these drugs carry a significant safety concern: amyloid-related imaging abnormalities, known as ARIA. ARIA occurs when removing amyloid from plaques disrupts blood vessel walls, leading to brain swelling or small bleeds. This risk is highest in people who carry the APOE-ε4 gene variant or who have pre-existing cerebral amyloid angiopathy.³⁰³¹ Regular MRI monitoring is required during treatment, and the decision to start these drugs involves weighing a meaningful but small clinical benefit against a tangible risk of brain vascular complications.

The Toll on Caregivers

Dementia’s impact extends well beyond the person diagnosed. Informal caregivers, usually family members, shoulder a physical and emotional burden that is well documented. A systematic review of 46 intervention programs for dementia caregivers found that burden, depression, and quality of life were the most frequently studied outcomes. About half the programs showed positive effects on at least one of these, with caregiver burden improving most often. Psychoeducational programs and cognitive-behavioral therapy, delivered either individually or in groups, were the most common approaches.³²³³

The economic scale of this caregiving is staggering. In the United States alone, direct medical costs for Alzheimer’s and related dementias reached roughly $196 billion in 2020, and the value of unpaid caregiver time added an estimated $254 billion more, making dementia care comparable in cost to the nation’s biggest public health challenges.³⁴ Globally, the societal costs of dementia in 2019 were estimated at about $1.3 trillion for roughly 55 million people living with the condition. Half of that total came from informal care.³⁵ Projections suggest that the global economic burden could reach $16.9 trillion by 2050, with the steepest proportional increases expected in low- and middle-income countries where formal care infrastructure is least developed.³⁶

Digital Tools for Earlier Detection

One of the newer frontiers in dementia research involves using everyday technology to spot cognitive changes before a person or their family notices anything is wrong. Speech analysis is a leading candidate. Subtle shifts in word-finding speed, sentence complexity, and pausing patterns can signal the earliest stages of cognitive decline, and these can be detected by algorithms analyzing a few minutes of recorded speech.³⁷ The appeal is obvious: unlike a blood test or brain scan, a speech assessment is inexpensive, noninvasive, and could be embedded in a routine telehealth visit or even a smartphone app. The field is still young, and no speech-based tool has replaced a clinical evaluation, but the trajectory suggests these digital biomarkers will eventually serve as a screening layer that flags who needs further workup, much the way a blood pressure cuff flags who needs a cardiac evaluation.

1
PubMed Central. Mechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer’s Disease ↩︎
2
PubMed Central. Advances in Amyloid-β Clearance in the Brain and Periphery: Implications for Neurodegenerative Diseases ↩︎
3
PubMed Central. The role of tau in Alzheimer’s disease and related disorders ↩︎
4
Nature Communications. Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease ↩︎
5
PubMed Central. Microglia and inflammation in Alzheimer’s disease ↩︎
6
PubMed. Alzheimer’s Disease and Vascular Dementia, Connecting and Differentiating Features ↩︎
7
PubMed Central. The overlap between vascular disease and Alzheimer’s disease – lessons from pathology ↩︎
8
PubMed Central. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both ↩︎
9
PubMed. Alzheimer’s disease and Lewy body disease: a comparative clinicopathological study ↩︎
10
Brain. Atrophy network mapping of clinical subtypes and main symptoms in frontotemporal dementia ↩︎
11
PubMed Central. Limbic-predominant age-related TDP-43 encephalopathy in the oldest old: a population-based study ↩︎
12
PubMed Central. The association of Lewy bodies with limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes and their role in cognition and Alzheimer’s dementia in older persons ↩︎
13
PubMed Central. The genes associated with early-onset Alzheimer’s disease ↩︎
14
PLoS Medicine. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases ↩︎
15
PubMed Central. Alzheimer’s Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function ↩︎
16
PubMed Central. Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer’s disease in clinical and community cohorts ↩︎
17
eBioMedicine. Diagnostic performance of the Lumipulse G pTau217 plasma assay across the Alzheimer’s disease continuum ↩︎
18
PubMed Central. Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer’s disease pathology ↩︎
19
Hypertens Res. Roles of vascular risk factors in the pathogenesis of dementia ↩︎
20
JAMA Otolaryngology–Head & Neck Surgery. Association of Age-Related Hearing Loss With Cognitive Function, Cognitive Impairment, and Dementia: A Systematic Review and Meta-analysis ↩︎
21
PubMed Central. Relationship of Hearing loss and Dementia: a Prospective, Population-based Study ↩︎
22
PubMed Central. Sleep‐Dependent Clearance of Brain Metabolites via the Glymphatic System: Implications for Alzheimer’s Pathophysiology ↩︎
23
PubMed Central. Cognitive reserve in ageing and Alzheimer’s disease ↩︎
24
PubMed Central. Cognitive reserve over the life course and risk of dementia: a systematic review and meta-analysis ↩︎
25
PLoS ONE. Education and Dementia in the Context of the Cognitive Reserve Hypothesis: A Systematic Review with Meta-Analyses and Qualitative Analyses ↩︎
26
PubMed Central. Impact of physical exercise on the regulation of brain-derived neurotrophic factor in people with neurodegenerative diseases ↩︎
27
PubMed Central. Donepezil for dementia due to Alzheimer’s disease ↩︎
28
PubMed Central. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials ↩︎
29
PubMed Central. Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions ↩︎
30
PubMed Central. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics ↩︎
31
PubMed Central. Amyloid-Related Imaging Abnormalities in the Era of Anti-Amyloid Beta Monoclonal Antibodies for Alzheimer’s Disease: Recent Updates on Clinical and Imaging Features and MRI Monitoring ↩︎
32
PubMed Central. Psychosocial interventions to support the mental health of informal caregivers of persons living with dementia – a systematic literature review ↩︎
33
PubMed Central. Interventions to Relieve the Burden on Informal Caregivers of Older People with Dementia: A Scoping Review ↩︎
34
npj aging. Cost of care for Alzheimer’s disease and related dementias in the United States: 2016 to 2060 ↩︎
35
PubMed Central. The worldwide costs of dementia in 2019 ↩︎
36
The Lancet Regional Health / eClinicalMedicine. Projecting the global, regional, and national economic burden of Alzheimer’s disease and related dementias from 2019 to 2050: a modeling study ↩︎
37
PubMed Central. Harnessing Speech-Derived Digital Biomarkers to Detect and Quantify Cognitive Decline Severity in Older Adults ↩︎